Retail Clinics

DALLAS — The market for electronic medical records in the United States may exceed $6 billion in value in five years, according to a new report by research firm MarketsandMarkets.

In the report, “U.S. Electronic Medical Records (EMR) Market, 2010-2015 (Market Share, Winning Strategies and Adoption Trends),” released this month, the firm said that the market was expected to grow from $2.17 billion in 2009 to $6.05 billion in 2015.

RICHMOND, Va. — Patients who used a calendar blister packaging system for their medications showed greater medication adherence than those using traditional vials, according to a new study published in the journal Clinical Therapeutics.

SILVER SPRING, Md. — One month after the observance of Skin Cancer Awareness Month, the Food and Drug Administration announced Tuesday it is taking measures to assure all sunscreen products are safe and effective.

NEW YORK — Sunbow officially unveiled at a press event in New York on Wednesday its new line of sun care products specially designed for children.

The new product line is comprised of seven SKUs formulated with micronized zinc oxide formulas to provide a strong UVA/UVB barrier without the chemical actives, such as oxybenzone or octinoxate.

ALLEGAN, Mich. — Teva Pharmaceutical Industries has begun shipping a generic drug for allergies, partnering company Perrigo said Wednesday.

Triamcinolone acetonide nasal spray is a generic version of Sanofi’s Nasacort AQ and is used to treat nasal symptoms of seasonal and year-round allergies in patients ages 6 years and older. The Food and Drug Administration approved the generic version of the drug in 2009. The generic was made by Barr Labs, which Teva acquired a few years ago.

INDIANAPOLIS — A new oral medication for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim has become available in pharmacies, the companies said Wednesday.

Lilly and BI announced the availability of Tradjenta (linagliptin) in chain and independent pharmacies around the country.

MADISON, Miss. — The Food and Drug Administration has approved two cough-cold medications made by Cypress Pharmaceutical, the company said Monday.

Cypress announced the approval of Zutripro (hydrocodone bitartrate, chlorpheniramine maleate and pseudoephedrine hydrochloride) and Rezira (hydrocodone bitartrate and pseudoephedrine). Both drugs are oral solutions and, because they contain the opioid hydrocodone, are classified as schedule III controlled substances by the Drug Enforcement Administration. Cypress subsidiary Hawthorn Pharmaceuticals will market the drugs.

MORRISTOWN, N.J. — Bayer on Tuesday introduced its new Bayer Advanced Aspirin, billed as relieving pain “twice as fast” as the previous Extra Strength Bayer Aspirin.

Using a patent-pending Pro-Release technology, the particles in the new formulation are one-tenth the size of Extra Strength Bayer Aspirin and dissolve six times faster.